Formulation and Evaluation of Albuterol Metered Dose Inhalers Containing Tetrafluoroethane (P134a), a Non-CFC Propellant

ABSTRACT This study was undertaken to evaluate tetrafluoroethane (P134a) as a possible chlorofluorocarbon (CFC) replacement for albuterol metered dose inhaler (MDI) formulations. Preformulation studies using three conventional (oleic acid, sorbitan trioleate, lecithin) and a nonconventional (oleyl a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical development and technology 1998, Vol.3 (2), p.163-174
Hauptverfasser: Tiwari, Deepak, Goldman, David, Malick, Waseem A., Madan, Parshotam L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 174
container_issue 2
container_start_page 163
container_title Pharmaceutical development and technology
container_volume 3
creator Tiwari, Deepak
Goldman, David
Malick, Waseem A.
Madan, Parshotam L.
description ABSTRACT This study was undertaken to evaluate tetrafluoroethane (P134a) as a possible chlorofluorocarbon (CFC) replacement for albuterol metered dose inhaler (MDI) formulations. Preformulation studies using three conventional (oleic acid, sorbitan trioleate, lecithin) and a nonconventional (oleyl alcohol) surfactant indicated that PI 34a is a poor solvent for these surfactants. A slight improvement in the solubility of oleic acid and oleyl alcohol was observed by the addition of low concentrations of a nonconventional cosolvent diethyl ether (≤0.5% w/w). Formulation screening of the prepared albuterol formulations indicated that suspensions containing oleyl alcohol and diethyl ether had a slower rate of separation. Product performance of four albuterol formulations containing oleyl alcohol, diethyl ether, and PI 34a was evaluated and compared to a leading commercial formulation containing CFC propellants (Ventolin). Ventolin showed excellent agreement between the emitted dose and the expected dose but only a reasonable agreement was observed with one of the better P134a-containing formulations. PI 34a formulations showed higher internal pressure in comparison to the CFC formulation. The concentrations of the surfactant, drug, and cosolvent appeared to have a significant impact on the uniformity of the emitted dose. Determination of particle size using the time-of-flight and the laser diffraction analyzer revealed that PI 34a formulations had equal or smaller particle size than the formulation containing CFC. However, the CFC formulation showed a higher respirable fraction than the PI 34a formulation when measured by the two inertial impaction methods. The observed particle size distribution of the formulation appeared to depend on the measuring method used.
doi_str_mv 10.3109/10837459809028492
format Article
fullrecord <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_3109_10837459809028492</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79981193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-4440cb99bcd190aa21c64be02345a954d4a64bc2829edd75268feffb496416d43</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EKqXwAzgg-YAQSATs2E5swaUKXahUoIdyjibOhE3ltbe2A_Tf47JLJYTU03j8vjcaPxPylLM3gjPzljMtWqmMZobVWpr6Hjks921ldNPevzlrURWAPSSPUrpkjGvD1AE5MI0SrRKH5NcqxM3iIM_BU_AjPfkBbtm1YaLHblgyxuDoZywVR_ohJKSnfg0OY6Jd8BlmP_vv9AJzhMktIQbMa_BIX55zIeHVawr0S_BVt-roeQxbdA58fkweTOASPtnXI_JtdXLRfarOvn487Y7PKiukypWUktnBmMGO3DCAmttGDsjqooJRcpRQelvr2uA4tqpu9ITTNEjTSN6MUhyRF7u52xiuFky538zJ_tkBw5L61hjNuREF5DvQxpBSxKnfxnkD8brnrL9Ju_8v7eJ5th--DBscbx37eIv-fK9DsuCmCN7O6RarhVBS6YK932Gzn8p3wM8Q3dhnuHYh_vWIu7Z49499jeDy2kLE_jIs0Zd473jDbyierCs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79981193</pqid></control><display><type>article</type><title>Formulation and Evaluation of Albuterol Metered Dose Inhalers Containing Tetrafluoroethane (P134a), a Non-CFC Propellant</title><source>MEDLINE</source><source>Taylor &amp; Francis Medical Library - CRKN</source><source>Taylor &amp; Francis Journals Complete</source><creator>Tiwari, Deepak ; Goldman, David ; Malick, Waseem A. ; Madan, Parshotam L.</creator><creatorcontrib>Tiwari, Deepak ; Goldman, David ; Malick, Waseem A. ; Madan, Parshotam L.</creatorcontrib><description>ABSTRACT This study was undertaken to evaluate tetrafluoroethane (P134a) as a possible chlorofluorocarbon (CFC) replacement for albuterol metered dose inhaler (MDI) formulations. Preformulation studies using three conventional (oleic acid, sorbitan trioleate, lecithin) and a nonconventional (oleyl alcohol) surfactant indicated that PI 34a is a poor solvent for these surfactants. A slight improvement in the solubility of oleic acid and oleyl alcohol was observed by the addition of low concentrations of a nonconventional cosolvent diethyl ether (≤0.5% w/w). Formulation screening of the prepared albuterol formulations indicated that suspensions containing oleyl alcohol and diethyl ether had a slower rate of separation. Product performance of four albuterol formulations containing oleyl alcohol, diethyl ether, and PI 34a was evaluated and compared to a leading commercial formulation containing CFC propellants (Ventolin). Ventolin showed excellent agreement between the emitted dose and the expected dose but only a reasonable agreement was observed with one of the better P134a-containing formulations. PI 34a formulations showed higher internal pressure in comparison to the CFC formulation. The concentrations of the surfactant, drug, and cosolvent appeared to have a significant impact on the uniformity of the emitted dose. Determination of particle size using the time-of-flight and the laser diffraction analyzer revealed that PI 34a formulations had equal or smaller particle size than the formulation containing CFC. However, the CFC formulation showed a higher respirable fraction than the PI 34a formulation when measured by the two inertial impaction methods. The observed particle size distribution of the formulation appeared to depend on the measuring method used.</description><identifier>ISSN: 1083-7450</identifier><identifier>EISSN: 1097-9867</identifier><identifier>DOI: 10.3109/10837459809028492</identifier><identifier>PMID: 9653753</identifier><language>eng</language><publisher>New York, NY: Informa UK Ltd</publisher><subject>Aerosol ; Aerosol Propellants ; Air Pressure ; Albuterol - administration &amp; dosage ; Albuterol - analysis ; Alternate propellants ; Anti-Asthmatic Agents - administration &amp; dosage ; Anti-Asthmatic Agents - analysis ; Biological and medical sciences ; Chromatography, High Pressure Liquid ; Drug Compounding ; General pharmacology ; HFA-134 a ; Hydrocarbons, Halogenated ; Medical sciences ; Metered dose inhaler ; Non-CFC propellant ; P134a ; Particle size ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Respiratory system ; Solubility ; Surface-Active Agents ; Tetrafluoroethane</subject><ispartof>Pharmaceutical development and technology, 1998, Vol.3 (2), p.163-174</ispartof><rights>1998 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1998</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-4440cb99bcd190aa21c64be02345a954d4a64bc2829edd75268feffb496416d43</citedby><cites>FETCH-LOGICAL-c345t-4440cb99bcd190aa21c64be02345a954d4a64bc2829edd75268feffb496416d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/10837459809028492$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/10837459809028492$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4022,27921,27922,27923,59645,59751,60434,60540,61219,61254,61400,61435</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2335458$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9653753$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tiwari, Deepak</creatorcontrib><creatorcontrib>Goldman, David</creatorcontrib><creatorcontrib>Malick, Waseem A.</creatorcontrib><creatorcontrib>Madan, Parshotam L.</creatorcontrib><title>Formulation and Evaluation of Albuterol Metered Dose Inhalers Containing Tetrafluoroethane (P134a), a Non-CFC Propellant</title><title>Pharmaceutical development and technology</title><addtitle>Pharm Dev Technol</addtitle><description>ABSTRACT This study was undertaken to evaluate tetrafluoroethane (P134a) as a possible chlorofluorocarbon (CFC) replacement for albuterol metered dose inhaler (MDI) formulations. Preformulation studies using three conventional (oleic acid, sorbitan trioleate, lecithin) and a nonconventional (oleyl alcohol) surfactant indicated that PI 34a is a poor solvent for these surfactants. A slight improvement in the solubility of oleic acid and oleyl alcohol was observed by the addition of low concentrations of a nonconventional cosolvent diethyl ether (≤0.5% w/w). Formulation screening of the prepared albuterol formulations indicated that suspensions containing oleyl alcohol and diethyl ether had a slower rate of separation. Product performance of four albuterol formulations containing oleyl alcohol, diethyl ether, and PI 34a was evaluated and compared to a leading commercial formulation containing CFC propellants (Ventolin). Ventolin showed excellent agreement between the emitted dose and the expected dose but only a reasonable agreement was observed with one of the better P134a-containing formulations. PI 34a formulations showed higher internal pressure in comparison to the CFC formulation. The concentrations of the surfactant, drug, and cosolvent appeared to have a significant impact on the uniformity of the emitted dose. Determination of particle size using the time-of-flight and the laser diffraction analyzer revealed that PI 34a formulations had equal or smaller particle size than the formulation containing CFC. However, the CFC formulation showed a higher respirable fraction than the PI 34a formulation when measured by the two inertial impaction methods. The observed particle size distribution of the formulation appeared to depend on the measuring method used.</description><subject>Aerosol</subject><subject>Aerosol Propellants</subject><subject>Air Pressure</subject><subject>Albuterol - administration &amp; dosage</subject><subject>Albuterol - analysis</subject><subject>Alternate propellants</subject><subject>Anti-Asthmatic Agents - administration &amp; dosage</subject><subject>Anti-Asthmatic Agents - analysis</subject><subject>Biological and medical sciences</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Drug Compounding</subject><subject>General pharmacology</subject><subject>HFA-134 a</subject><subject>Hydrocarbons, Halogenated</subject><subject>Medical sciences</subject><subject>Metered dose inhaler</subject><subject>Non-CFC propellant</subject><subject>P134a</subject><subject>Particle size</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory system</subject><subject>Solubility</subject><subject>Surface-Active Agents</subject><subject>Tetrafluoroethane</subject><issn>1083-7450</issn><issn>1097-9867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhS0EKqXwAzgg-YAQSATs2E5swaUKXahUoIdyjibOhE3ltbe2A_Tf47JLJYTU03j8vjcaPxPylLM3gjPzljMtWqmMZobVWpr6Hjks921ldNPevzlrURWAPSSPUrpkjGvD1AE5MI0SrRKH5NcqxM3iIM_BU_AjPfkBbtm1YaLHblgyxuDoZywVR_ohJKSnfg0OY6Jd8BlmP_vv9AJzhMktIQbMa_BIX55zIeHVawr0S_BVt-roeQxbdA58fkweTOASPtnXI_JtdXLRfarOvn487Y7PKiukypWUktnBmMGO3DCAmttGDsjqooJRcpRQelvr2uA4tqpu9ITTNEjTSN6MUhyRF7u52xiuFky538zJ_tkBw5L61hjNuREF5DvQxpBSxKnfxnkD8brnrL9Ju_8v7eJ5th--DBscbx37eIv-fK9DsuCmCN7O6RarhVBS6YK932Gzn8p3wM8Q3dhnuHYh_vWIu7Z49499jeDy2kLE_jIs0Zd473jDbyierCs</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>Tiwari, Deepak</creator><creator>Goldman, David</creator><creator>Malick, Waseem A.</creator><creator>Madan, Parshotam L.</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><general>Informa Healthcare</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>Formulation and Evaluation of Albuterol Metered Dose Inhalers Containing Tetrafluoroethane (P134a), a Non-CFC Propellant</title><author>Tiwari, Deepak ; Goldman, David ; Malick, Waseem A. ; Madan, Parshotam L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-4440cb99bcd190aa21c64be02345a954d4a64bc2829edd75268feffb496416d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Aerosol</topic><topic>Aerosol Propellants</topic><topic>Air Pressure</topic><topic>Albuterol - administration &amp; dosage</topic><topic>Albuterol - analysis</topic><topic>Alternate propellants</topic><topic>Anti-Asthmatic Agents - administration &amp; dosage</topic><topic>Anti-Asthmatic Agents - analysis</topic><topic>Biological and medical sciences</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Drug Compounding</topic><topic>General pharmacology</topic><topic>HFA-134 a</topic><topic>Hydrocarbons, Halogenated</topic><topic>Medical sciences</topic><topic>Metered dose inhaler</topic><topic>Non-CFC propellant</topic><topic>P134a</topic><topic>Particle size</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory system</topic><topic>Solubility</topic><topic>Surface-Active Agents</topic><topic>Tetrafluoroethane</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tiwari, Deepak</creatorcontrib><creatorcontrib>Goldman, David</creatorcontrib><creatorcontrib>Malick, Waseem A.</creatorcontrib><creatorcontrib>Madan, Parshotam L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical development and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tiwari, Deepak</au><au>Goldman, David</au><au>Malick, Waseem A.</au><au>Madan, Parshotam L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formulation and Evaluation of Albuterol Metered Dose Inhalers Containing Tetrafluoroethane (P134a), a Non-CFC Propellant</atitle><jtitle>Pharmaceutical development and technology</jtitle><addtitle>Pharm Dev Technol</addtitle><date>1998</date><risdate>1998</risdate><volume>3</volume><issue>2</issue><spage>163</spage><epage>174</epage><pages>163-174</pages><issn>1083-7450</issn><eissn>1097-9867</eissn><abstract>ABSTRACT This study was undertaken to evaluate tetrafluoroethane (P134a) as a possible chlorofluorocarbon (CFC) replacement for albuterol metered dose inhaler (MDI) formulations. Preformulation studies using three conventional (oleic acid, sorbitan trioleate, lecithin) and a nonconventional (oleyl alcohol) surfactant indicated that PI 34a is a poor solvent for these surfactants. A slight improvement in the solubility of oleic acid and oleyl alcohol was observed by the addition of low concentrations of a nonconventional cosolvent diethyl ether (≤0.5% w/w). Formulation screening of the prepared albuterol formulations indicated that suspensions containing oleyl alcohol and diethyl ether had a slower rate of separation. Product performance of four albuterol formulations containing oleyl alcohol, diethyl ether, and PI 34a was evaluated and compared to a leading commercial formulation containing CFC propellants (Ventolin). Ventolin showed excellent agreement between the emitted dose and the expected dose but only a reasonable agreement was observed with one of the better P134a-containing formulations. PI 34a formulations showed higher internal pressure in comparison to the CFC formulation. The concentrations of the surfactant, drug, and cosolvent appeared to have a significant impact on the uniformity of the emitted dose. Determination of particle size using the time-of-flight and the laser diffraction analyzer revealed that PI 34a formulations had equal or smaller particle size than the formulation containing CFC. However, the CFC formulation showed a higher respirable fraction than the PI 34a formulation when measured by the two inertial impaction methods. The observed particle size distribution of the formulation appeared to depend on the measuring method used.</abstract><cop>New York, NY</cop><pub>Informa UK Ltd</pub><pmid>9653753</pmid><doi>10.3109/10837459809028492</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1083-7450
ispartof Pharmaceutical development and technology, 1998, Vol.3 (2), p.163-174
issn 1083-7450
1097-9867
language eng
recordid cdi_informahealthcare_journals_10_3109_10837459809028492
source MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete
subjects Aerosol
Aerosol Propellants
Air Pressure
Albuterol - administration & dosage
Albuterol - analysis
Alternate propellants
Anti-Asthmatic Agents - administration & dosage
Anti-Asthmatic Agents - analysis
Biological and medical sciences
Chromatography, High Pressure Liquid
Drug Compounding
General pharmacology
HFA-134 a
Hydrocarbons, Halogenated
Medical sciences
Metered dose inhaler
Non-CFC propellant
P134a
Particle size
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Respiratory system
Solubility
Surface-Active Agents
Tetrafluoroethane
title Formulation and Evaluation of Albuterol Metered Dose Inhalers Containing Tetrafluoroethane (P134a), a Non-CFC Propellant
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T06%3A07%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formulation%20and%20Evaluation%20of%20Albuterol%20Metered%20Dose%20Inhalers%20Containing%20Tetrafluoroethane%20(P134a),%20a%20Non-CFC%20Propellant&rft.jtitle=Pharmaceutical%20development%20and%20technology&rft.au=Tiwari,%20Deepak&rft.date=1998&rft.volume=3&rft.issue=2&rft.spage=163&rft.epage=174&rft.pages=163-174&rft.issn=1083-7450&rft.eissn=1097-9867&rft_id=info:doi/10.3109/10837459809028492&rft_dat=%3Cproquest_infor%3E79981193%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79981193&rft_id=info:pmid/9653753&rfr_iscdi=true